TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of head and neck cancer.

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with head and neck cancer.

LEARNING OBJECTIVES

• Appreciate the importance of interdisciplinary coordination when formulating a treatment plan for head and neck cancer, and recognize the roles that various specialists play in long-term patient care.
• Develop a plan to manage the short- and long-term adverse effects associated with multimodal management of localized and locally advanced head and neck cancer to support patient quality of life and continuation of treatment.
• Recall long-term outcomes with traditional treatment approaches for localized or locally advanced head and neck cancer, and assess clinical, biological and patient-specific factors that increase the risk of recurrence after primary therapy.
• Evaluate research findings with novel agents targeting inhibitors of apoptosis proteins in patients with locally advanced squamous cell carcinoma of the head and neck, and contemplate the potential role of this approach in clinical management.
• Appraise clinical trial data documenting the efficacy and safety of immune checkpoint inhibitors in various recurrent or metastatic head and neck cancer subtypes, and consider the current utility of these agents for newly diagnosed and progressive disease.
• Recall the design of ongoing clinical trials evaluating novel agents and strategies for head and neck cancer, and counsel appropriate patients about availability and participation.

ACCREDITATION STATEMENT
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CREDIT DESIGNATION STATEMENT
Video Program: This educational activity for 1.75 contact hours is provided by RTP during the period of May 2024 to May 2025.

This activity is awarded 1.75 ANCC pharmacotherapeutic contact hours.

ONCC/ILNA CERTIFICATION INFORMATION
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONS2024/HeadandNeck/ILNA.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

PRIVACY POLICY 
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. 

FOR SUCCESSFUL COMPLETION
Video Program: This NCPD activity consists of a video component. To receive credit, the participant should review the NCPD information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ONS2024/HeadandNeck/Video/NCPD.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Meetal Dharia, NP-C, AOCNP
Division of Hematology/Oncology
UCLA Health
Los Angeles, California

No relevant conflicts of interest to disclose.

Robert L Ferris, MD, PhD
Director, UPMC Hillman Cancer Center
Hillman Professor of Oncology
UPMC Senior Vice President for Oncology Programs
Associate Senior Vice Chancellor for Cancer Research
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Advisory Boards: Adaptimmune, Bristol Myers Squibb, Coherus BioSciences, CureVac, CytoAgents, Eisai Inc, Genmab US Inc, Hookipa Pharma Inc, Instil Bio, Lifescience Dynamics, MacroGenics Inc, MeiraGTx, Merck, Merus, Numab Therapeutics AG, Oncocyte, Pfizer Inc, Rakuten Medical Inc, Regeneron Pharmaceuticals Inc, Seagen Inc, SIRPant Immunotherapeutics Inc, Vir Biotechnology Inc; Clinical Trial, Research Funding: Bristol Myers Squibb.

Robert Haddad, MD
Chief, Division of Head and Neck Oncology
McGraw Chair in Head and Neck Oncology
Institute Physician
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

No relevant conflicts of interest to disclose.

Lynsey P Teulings, APRN
Nurse Practitioner
Head and Neck Medical Oncology
Smilow Cancer Hospital at Yale New Haven Health
New Haven, Connecticut

Advisory Committee: EMD Serono Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop NCPD activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Coherus BioSciences and EMD Serono Inc.

Release date: May 2024
Expiration date: May 2025

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.